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Introduction: It remains challenging to predict the outcomes of therapy in patients with rheumatoid arthritis (RA).
The objective of this study was to identify immune response signatures that correlate with clinical treatment
outcomes in patients with RA.
Methods: A cohort of 71 consecutive patients with early RA starting treatment with disease-modifying antirheumatic
drugs (DMARDs) was recruited. Disease activity at baseline and after 21 to 24 weeks of follow-up was measured using
the Disease Activity Score in 28 joints (DAS28). Immune response profiling was performed by analyzing multi-cytokine
production from peripheral blood cells following incubation with a panel of stimuli, including a mixture of human
cytomegalovirus (CMV) and Epstein-Barr virus (EBV) lysates. Profiles identified via principal components analysis (PCA)
for each stimulus were then correlated with the ΔDAS28 from baseline to follow-up. A clinically meaningful
improvement in the DAS28 was defined as a decrease of ≥1.2.
Results: A profile of T-cell cytokines (IL-13, IL-4, IL-5, IL-2, IL-12, and IFN-γ) produced in response to CMV/EBV
was found to correlate with the ΔDAS28 from baseline to follow-up. At baseline, a higher magnitude of the
CMV/EBV immune response profile predicted inadequate DAS28 improvement (mean PCA-1 scores: 65.6 versus
50.2; P = 0.029). The baseline CMV/EBV response was particularly driven by IFN-γ (P = 0.039) and IL-4 (P = 0.027).
Among patients who attained clinically meaningful DAS28 improvement, the CMV/EBV PCA-1 score increased
from baseline to follow-up (mean +11.6, SD 25.5), whereas among patients who responded inadequately to
DMARD therapy, the CMV/EBV PCA-1 score decreased (mean −12.8, SD 25.4; P = 0.002). Irrespective of the
ΔDAS28, methotrexate use was associated with up-regulation of the CMV/EBV response. The CMV/EBV profile
was associated with positive CMV IgG (P <0.001), but not EBV IgG (P = 0.32), suggesting this response was
related to CMV exposure.
Conclusions: A profile of T-cell immunity associated with CMV exposure influences the clinical response to
DMARD therapy in patients with early RA. Because CMV latency is associated with greater joint destruction,
our findings suggest that changes in T-cell immunity mediated by viral persistence may affect treatment
response and possibly long-term outcomes of RA.* Correspondence: davis.john4@mayo.edu
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The ideal approach for predicting and monitoring the
outcomes of treatment in rheumatoid arthritis (RA)
remains elusive. The advent of intensive, goal-directed
treatment strategies, employing combinations of syn-
thetic as well as biologic disease-modifying antirheu-
matic drugs (DMARDs), has substantially improved the
prognosis of this disease [1]. However, many patients still
fail to achieve low disease activity or remission [2-4]. Fail-
ure to completely abrogate inflammation puts patients at
risk for disease progression, including joint destruction,
disability, impaired quality of life, cardiovascular disease,
and premature death [5,6].
The complexity of this issue emerges with the realization
that, at times, discriminating clinical signs and symptoms
of active joint inflammation from non-inflammatory joint
disease or chronic pain syndromes is challenging [7-9].
With many synthetic and biologic DMARDs now available,
our limited ability to predict and to efficiently judge the
likely outcomes of DMARD therapy represents a critical
barrier to the development of more effective treatment
strategies using these agents.
Recently, we have established an approach of immune-
response profiling for the discovery of complex bio-
markers predictive of treatment response [10]. Although
the levels of serum cytokines have proven to be disap-
pointing for use as disease biomarkers [10-14], our work
has suggested that immune response signatures may
provide greater biologically relevant information. The re-
sults of our published studies demonstrate proof of
principle that our approach, based on multiplexed ana-
lysis of ex vivo cytokine production in response to broad
stimulation, can identify profiles of immune function as-
sociated with radiographic joint damage as well as myo-
cardial disease in patients with RA [10,15]. Further, the
discovery of a correlation between a profile of immune
response to Epstein-Barr virus (EBV) and human cyto-
megalovirus (CMV) and the severity of radiographic
joint destruction in RA demonstrates the relevance of
the data generated to the investigation of pathogenesis
[16]. The purpose of this study was to identify immune
response signatures that are associated with treatment
outcomes in patients with early RA.
Methods
Study design and participants
A 24-week prospective observational cohort study of pa-
tients with newly diagnosed RA was performed at our
institution. Consecutive patients with a new diagnosis of
inflammatory arthritis during the enrollment period of
July 2008 to December 2010 were referred for screening
by rheumatologists in our division. At conception of this
study, the available classification criteria for RA were the
1987 criteria, which were too insensitive in early diseasefor use in this study (which took place before the 2010 re-
vised classification criteria were published) [17]. There-
fore, the Leiden early RA prediction rule was used [18,19].
Eligible patients were required to have a score ≥8 on the
early RA prediction rule and to be starting their initial
treatment with conventional DMARDs within 3 weeks of
diagnosis. Patients who were prescribed biologic agents
were ineligible. All patients (n = 71) participated in re-
search study visits at baseline and after 21 to 24 weeks of
follow up. Patients were required to provide written in-
formed consent prior to study participation. The insti-
tutional review board of the Mayo Foundation approved
this study.Data collection
During each research study visit, one consultant rheu-
matologist (JMD) performed a standardized clinical evalu-
ation of the patient, consisting of the 68-tender joint count,
the 66-swollen joint count and the physician global assess-
ment (0 to 100 mm). All patients completed the study
questionnaire, which included visual analog scales (0 to
100 mm) for the levels of pain, fatigue and the patient glo-
bal assessment of disease activity, and the Health As-
sessment Questionnaire (HAQ) disability index [20,21].
The dates of initiation/change, dosages, and route (that is,
oral or intra-articular) of DMARDs or corticosteroids were
obtained from the patients and confirmed in the most re-
cent outpatient medication list. Medical records were
reviewed to collect relevant demographic information,
symptom duration at baseline, body mass index (kg/m2),
smoking status (current, former, or never), and test results
for rheumatoid factor (RF) and anti-citrullinated protein
antibodies (ACPA). C-reactive protein (CRP) was measured
by turbidometric assay (Roche Diagnostics, Indianapolis,
Indiana, USA). Enzyme-linked immunosorbent assays were
done to assess past CMV infection or exposure using the
VIDAS® CMV IgG (bioMerieux, Inc., Marcy l'Etoile,
France), and multiplexed immunoassays were done to as-
sess past EBV infection using the BioPlex™ 2200 System
assessing EBV IgG and IgM (Bio-Rad Laboratories,
Hercules, California, USA).Definition of outcome measures
Clinical disease activity was defined by the Disease
Activity Score in 28 joints (DAS28), based on the
four-variable version using CRP [22,23]. Physical dis-
ability was defined by the HAQ disability index.
Treatment response was defined as the difference (Δ)
between the baseline and 21- to 24-week values for
the DAS28 and HAQ disability index. A clinically
meaningful improvement in the DAS28 was defined
as a decrease ≥1.2.
Table 1 Characteristics at baseline and follow up of the
71 patients with early RA
Variable Baseline Follow up P
Age 56.4 (12.7) - -
Female 47 (66%) - -
Duration of symptoms, months 10.3 (11.6) - -
Smoking status (current) 15 (21%) - -
Body mass index (kg/m2) 30.6 (7.2) - -
Rheumatoid factor-positive 55 (79%) - -
ACPA-positive 63 (89%) - -
CMV-IgG-positive 30 (42%) - -
EBV-IgG-positive 64 (90%) - -
DAS28-CRP (four-variable) 4.9 (1.0) 3.6 (1.3) <0.001
HAQ disability index 0.9 (0.5) 0.5 (0.6) <0.001
C-reactive protein (mg/L) 12.6 (18.0) 6.3 (7.9) 0.003
Data are mean (SD) or number (%) as appropriate. RA, rheumatoid arthritis;
ACPA, anti-citrullinated protein antibodies; DAS28, Disease Activity Score in 28
joints; HAQ, Health Assessment Questionnaire; CMV, cytomegalovirus; EBV,
Epstein-Barr virus; DMARD, disease-modifying antirheumatic drug.
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Immune-response profiling was performed on samples
obtained from all 71 patients at the baseline visit and
from a subset of 43 patients at the 21- to 24-week visit.
Detailed methods of our approach to profiling the sys-
temic immune response were previously described [10].
Briefly, peripheral blood mononuclear cells (PBMC)
from patients were cultured in the presence of a panel of
six stimuli, or in media alone, for 48 hours. Stimuli used
were immobilized anti-CD3/anti-CD28 monoclonal anti-
bodies (anti-CD3/anti-CD28), combined lysates of puri-
fied CMV and EBV, containing both viral peptides and
DNA, phytohemagglutinin (PHA), phorbol myristate
acetate with ionomycin (PMA/ionomycin), a mixture of
staphylococcal enterotoxins A and B (SEA/SEB), and
CpG oligonucleotides. At 48 hours of culture, cell-free
supernatants were removed and frozen for subsequent
cytokine analysis.
The production of cytokines in the supernatants was
analyzed using the MSD® 96-well MULTI-SPOT® Human
Cytokine Assays tissue culture kit (Meso Scale Discovery
(MSD), Rockville, Maryland, USA). The cytokine panel
included IL-1β, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8 (CXCL8),
IL-10, IL-12, IL-13, IL-17A, IFN-γ, TNF-α, monocyte
chemoattractant protein (MCP)-1 (CCL2), monocyte
inflammatory protein (MIP)-1β (CCL4), granulocyte col-
ony stimulating factor (G-CSF), and granulocyte mono-
cyte colony stimulating factor (GM-CSF).
Statistical analysis
The baseline characteristics were analyzed using descrip-
tive statistics, including mean (SD) or median (range) as
appropriate. All statistical tests were two-sided; the
significance level was set at 0.05 for all analyses.
Paired t-tests were used to assess changes in charac-
teristics between baseline and follow-up visits. Mixed
models were used to normalize the cytokine data and ad-
just for age and sex as previously described [10]. Principal
components analysis (PCA) was used to derive immune-
response profiles based on the first and second principal
components of ex vivo cytokine production for each
stimulus [16]. This analytic technique provided a relative
weighting of cytokine importance in each profile and
quantitatively summarized the information in immune-
response profiles as PCA scores (rescaled 0 to 100 for in-
terpretation) for subsequent screening.
Spearman methods and Wilcoxon rank sum tests were
used to test for associations of both the baseline im-
mune response PCA scores and the changes in these
scores from baseline to 21 to 24 weeks with the changes
in the clinical disease activity measures from baseline to
21 to 24 weeks. For immune profiles significantly associ-
ated with treatment response, partial Spearman correl-
ation was used to adjust for potential confoundingfactors, including age, sex, body mass index, smoking
status, RF status, ACPA status, CMV immunoglobulin
(Ig)G, EBV IgG, methotrexate use, and prednisone use.
Results
Baseline patient characteristics
A total of 71 patients with early RA according to the
Leiden early RA prediction rule were recruited. Of these,
39 (55%) also fulfilled the 1987 American College of
Rheumatology (ACR) classification criteria. The mean
(SD) age of the cohort was 56 (13) years, and 47 (66%)
were female (Table 1). The median duration of symp-
toms was 5.5 months (range 0.5 to 45.5). About 90%
were ACPA positive. At baseline, the mean (SD) DAS28
was 4.9 (1.0), consistent with moderately high disease-
activity, and the mean (SD) HAQ disability index was
0.9 (0.5), corresponding to mild-to-moderate disability.
At the baseline visit, 27 (38%) patients had already taken
their first dose of oral DMARDs, and 16 (23%) were on
prednisone (Table 2). The remainder of patients began
DMARDs and/or prednisone after the initial study blood
draw.
Initial DMARD therapy was prescribed by each pa-
tient’s primary rheumatologist: 49 patients (69%) re-
ceived single-drug therapy with methotrexate, 24 (34%)
received hydroxychloroquine, 10 (14%) received double-
or triple-DMARD combination therapy, and 4 (6%) re-
ceived other DMARDs (Table 2). Forty-six patients (65%)
were also treated initially with prednisone. Treatment with
DMARDs and prednisone during the study is shown in
Table 2.
By follow up at 21 to 24 weeks, significant clinical im-
provements were noted (Table 1). The median ΔDAS28
Table 2 Characteristics of exposure to DMARDs during follow up among 71 patients with early RA
Medication Baseline Follow up
Prior to baseline Prescribed at baseline visit Cumulative exposure Taking at follow-up visit
Methotrexate 14 (20%) 49 (69%) 51 (72%) 50 (70%)
Hydroxychloroquine 8 (11%) 24 (34%) 44 (39%) 28 (39%)
Combination DMARD 5 (7%) 10 (14%) 17 (24%) 16 (23%)
Prednisone 16 (23%) 46 (65%) 49 (69%) 29 (41%)
Dose, mean ± SD 17.4 ± 14.2 6.7 ± 5.6
Median (minimum, maximum) 10.0 (5, 75) 5 (1, 25)
Medications prescribed at the baseline visit include initiation within 2 weeks after baseline. DMARD, disease-modifying antirheumatic drug.
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ability index was −0.5 (range −2.1, 1.0). Significant
predictors of the ΔDAS28 from baseline to follow up
were age, baseline DAS28 and smoking status (data
not shown).
Discovery of immune response profiles
Profiles of cytokine release from PBMC into culture
supernatants in response to the various stimuli were
identified using PCA analysis (Table 3). For CMV/EBV
stimulation, PCA of the first principal component
(PCA-1) revealed an immune response profile consisting
of type 1 and type 2 T-cell cytokines. Selecting cytokines
with PCA weightings >0.5, the profile (ordered from
high to low weightings) included IL-13, IL-4, IL-5, IL-2,Table 3 Principal components analysis identifies immune resp
cytokine production in 71 patients with early RA
Cytokine CD3/CD28 CMV/EBV CpG
G-CSF −0.158 0.112 −0.224 0.540 0.736 −0.095
GM-CSF 0.202 0.795 0.186 0.828 0.438 −0.005 0.3
IFN-γ 0.709 0.101 0.690 0.176 0.495 0.013 0.7
IL-1β 0.178 0.202 0.086 0.306 0.722 −0.116 0.2
IL-2 0.693 0.298 0.798 0.211 −0.194 0.291 0.5
IL-4 0.783 0.103 0.898 0.152 −0.055 0.932 0.8
IL-5 0.189 0.184 0.858 0.104 −0.083 0.739 0.8
IL-6 0.101 0.716 −0.320 0.495 0.632 −0.107 0.2
IL-7 0.154 0.181 0.013 −0.102 −0.018 0.051 0.1
IL-8 0.177 −0.502 −0.117 −0.386 −0.727 0.146 −0.2
IL-10 0.830 0.152 0.328 −0.142 0.085 0.075 0.7
IL-12 0.755 −0.174 0.787 0.110 −0.216 0.880 0.6
IL-13 0.377 0.254 0.908 0.159 0.104 0.413 0.7
IL-17 0.157 0.786 0.369 0.787 0.024 0.073 0.2
MCP-1 −0.703 0.311 0.305 0.759 0.510 −0.109 0.2
MIP-1β 0.484 0.247 0.100 0.444 0.543 −0.010 0.6
TNF-α 0.765 0.424 0.268 0.159 0.805 0.018 0.6
Shown are the loadings for each cytokine in the first (left column for each stimulus
CMV, cytomegalovirus; EBV, Epstein-Barr virus; CpG, CpG oligonucleotides; PHA, phy
staphylococcal enterotoxins A and B; G-CSF, granulocyte colony stimulating factor;
IL, interleukin; MCP-1, monocyte chemoattractant protein 1; MIP-1β, monocyte inflaIL-12, and IFN-γ. The immune response profile for PHA
similarly reflected a T-cell response, comprising IL-4, IL-5,
IL-10, IL-13, IFN-γ, IL-12, MIP-1β, TNF-α, and IL-2.
Using the same selection criteria, the profile of basal cyto-
kine production in media alone for the second princi-
pal component (PCA-2) included IL-1β, IFN-γ, G-CSF,
TNF-α, and IL-6.
Correlation of the baseline immune response profiles
with treatment outcomes
The next step was to screen the immune response pro-
files identified at baseline for correlation with the clinical
outcomes at follow up (Table 4). The baseline CMV/
EBV PCA-1 score (r = 0.38, P = 0.007) and the baseline
media-alone PCA-2 score (r = 0.31, P = 0.034) wereonse profiles defined by multiplexed detection of ex vivo
PHA PMA SEA/SEB Media
- 0.933 0.802 −0.131 0.883 0.085 0.334 0.564
00 0.225 0.700 0.343 0.706 0.388 0.829 0.111
08 0.523 0.144 0.283 0.061 0.613 0.196 0.623
24 0.722 0.568 0.093 0.609 0.561 0.196 0.685
86 0.089 0.136 0.418 0.243 0.422 0.167 −0.055
92 0.165 −0.047 0.647 0.020 −0.040 −0.069 −0.131
25 0.260 −0.005 0.207 0.095 0.217 −0.138 −0.029
98 0.820 0.772 0.012 0.827 0.319 0.642 0.532
41 0.343 0.349 0.076 0.030 0.055 0.133 0.030
33 −0.748 −0.925 0.088 −0.480 −0.656 −0.151 −0.394
90 0.320 −0.006 0.469 0.145 0.060 0.121 0.130
86 0.009 −0.058 0.800 −0.051 −0.004 −0.098 −0.128
77 0.375 0.316 0.209 0.170 0.038 0.036 0.025
47 0.054 0.283 0.207 0.841 0.175 0.612 0.054
52 0.650 0.682 −0.067 0.798 0.047 0.775 0.253
81 0.519 0.147 0.660 0.362 0.376 0.591 0.357
61 0.584 0.768 0.448 0.228 0.750 0.600 0.539
) and the second (right column for each stimulus) principal components.
tohemagglutinin; PMA, phorbol myristate acetate with ionomycin; SEA/SEB,
GM-CSF, granulocyte monocyte colony stimulating factor; IFN, interferon;
mmatory protein 1-beta; TNF-α, tumor necrosis factor-α.
Table 4 Association of the baseline immune-response
profiles with the clinical outcomes of initial therapy at 21
to 24 weeks of follow up in 71 patients with RA
ΔDAS28 ΔHAQ-DI
Profile Model r P r P
CMV/EBV-1 Unadjusted 0.28b 0.03b −0.05 0.65
Adjusteda 0.38b 0.007b 0.08 0.59
CMV/EBV-2 Unadjusted −0.01 0.94 −0.18 0.13
Adjusteda 0.04 0.79 −0.13 0.36
PHA-1 Unadjusted 0.03 0.81 0.03 0.80
Adjusteda 0.02 0.91 −0.01 0.93
PHA-2 Unadjusted 0.16 0.23 0.10 0.42
Adjusteda 0.13 0.40 0.09 0.56
Media-1 Unadjusted 0.22 0.09 0.10 0.41
Adjusteda 0.27 0.064 0.19 0.20
Media-2 Unadjusted 0.26b 0.04b 0.12 0.33
Adjusteda 0.31b 0.034b 0.19 0.20
Shown are the Spearman correlations between the PCA stimulus-cytokine
scores for the first and second principal components and both the change in
the DAS28 and the change in the HAQ disability index from baseline to 21 to
24 weeks. aAdjusted for age, sex, body mass index, smoking status, RF status,
ACPA status, CMV IgG status, methotrexate use, and prednisone use; bvalues
are statistically significant. DAS28, Disease Activity Score in 28 joints; HAQ-DI,
Health Assessment Questionnaire disability index; CMV/EBV, cytomegalovirus/
Epstein-Barr virus; PHA, phytohemagglutinin; RF, rheumatoid factor; ACPA,
anti-citrullinated protein antibodies.
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adjusting for clinical covariates, including age, sex, body
mass index, smoking status, RF status, ACPA status,
CMV IgG status, methotrexate use, and prednisone use.
However, correlations of both CMV/EBV PCA-1 and
media-alone PCA-2 with ΔHAQ did not reach statistical
significance.
As shown in Figure 1A, patients who failed to achieve
clinically meaningful DAS28 improvement had a signifi-
cantly higher CMV/EBV PCA-1 score at baseline than pa-
tients who responded well to DMARD therapy (mean 65.6
versus 50.2, P = 0.029). Higher CMV/EBV PCA-1 scores
in non-responders were driven mainly by increased CMV/
EBV-induced IFN-γ (Figure 1D) and IL-4 (Figure 1G).
The baseline scores for CMV/EBV PCA-2 and media
alone PCA-2 were similar between responders and non-
responders (Figure 1B-C).
Of note, significant correlation with treatment out-
come was not found for the immune response profiles of
CPG or PHA (Table 4), or any of the other stimuli (data
not shown).
Correlation of the changes in immune response profiles
from baseline to follow up with changes in clinical
disease status
The subsequent analysis tested correlation between the
changes in the immune response profiles and the changesin clinical disease activity and disability from baseline to
follow up in a subset of 43 patients with complete data at
both visits (Table 5). The change in the CMV/EBV PCA-1
score was found to correlate significantly with the
ΔDAS28 from baseline to follow-up (r = −0.39, P = 0.032),
after adjusting for clinical covariates. As shown in
Figure 2A, among patients who attained clinically
meaningful DAS28 improvement, the mean CMV/
EBV PCA-1 score increased from baseline to follow
up (mean +11.6, SD 25.5), whereas among patients
who responded inadequately to DMARD therapy, the
CMV/EBV PCA-1 score decreased (mean −12.8, SD 25.4;
P = 0.002). Among patients who experienced augmenta-
tion of their CMV/EBV immune response, this effect was
consistent across all of the six T-cell cytokines (data not
shown). Similar results were observed for the change in
HAQ disability index, underscoring the robustness of
these results.
In contrast, the changes in both the media alone PCA-
1 and PCA-2 scores were shown to correlate with the
ΔDAS28 only after adjustment for the aforementioned
covariates. Comparison of the media-alone PCA scores
revealed no significant differences between responders
and non-responders to DMARD treatment (Figure 2B).
Pertinently, evidence of correlation with the ΔDAS28
was neither observed for the immune response profiles
of PHA or CPG (Table 5), nor any of the other stimuli
tested (data not shown).
Correlative analysis of the CMV/EBV immune response
with the change in clinical disease activity according to
DMARD treatment
Among the treatment non-responders, there was no evi-
dence that DMARD therapy had any impact on the CMV/
EBV PCA-1 immune response signature (Figure 3). How-
ever, among the patients who attained clinically meaning-
ful DAS28 improvement, methotrexate use during the
study was associated with a statistically significant increase
in the CMV/EBV PCA-1 score from baseline to follow up
(P = 0.004) (Figure 3). No significant associations between
the change in CMV/EBV PCA-1 score and the use of
methotrexate or corticosteroids were observed (data not
shown). Although the baseline CMV/EBV PCA-1 score
was correlated with the change in this score from baseline
to follow up (r = −0.44), adjustment for the baseline
CMV/EBV score did not change the relationship between
methotrexate use and the changes in the CMV/EBV PCA-
1 score.
Exploration of the immune response profile for CMV/EBV
Having observed associations between the CMV/EBV
immune-response profile and treatment response, we ex-
plored the relationships of this profile to clinical character-
istics. The baseline CMV/EBV PCA-1 score did not
Figure 1 Association between the baseline immune response signatures for cytomegalovirus/Epstein-Barr virus (CMV/EBV) and media
alone and clinical improvement at 21 to 24 weeks among 71 patients with early rheumatoid arthritis. (A-C) Shown are box plots for the
distributions of the CMV/EBV PCA-1, CMV/EBV PCA-2, and media alone PCA-2 scores, respectively, comparing responders and non-responders to
initial disease-modifying treatment. Values were scaled from 0 to 100. (D-I) Shown are box plots representing the distributions of individual
cytokines in the CMV/EBV PCA-1 signature in pg/mL. Clinical response was defined by a decrease in the DAS28 ≥1.2 from baseline to follow up.
PCA, principal components analysis; DAS28, disease activity score in 28 joints.
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status, ACPA status, baseline DAS28, or baseline HAQ
(data not shown). With regard to the potential for treat-
ment effects on the CMV/EBV immune response, the
mean CMV/EBV PCA-1 score at baseline was similar be-
tween prednisone users and non-users (61.3 versus 52.4, re-
spectively; P = 0.2) and between patients who had and
those who had not started taking DMARDs prior to base-
line (58.7 versus 59.6, respectively; P = 0.78). Interestingly,
the change in the CMV/EBV PCA-1 score from baseline to
follow up was associated with RF positivity (median differ-
ence −16.1 in RF-negative versus −0.33 in RF-positive, P =
0.03). In contrast, the CMV/EBV PCA-2 score, which was
not associated with treatment outcome, was associated with
baseline DAS28 (r = 0.34; P = 0.004), baseline HAQ (r =
0.25; P = 0.04), and prior prednisone use (median 62.7 forno prior prednisone use versus 85.9 for prior prednisone
use; P = 0.03).
The CMV/EBV PCA-1 score, which represented the
immune response to a mixture of viral lysates, was
associated with CMV exposure (median 48.6 among
CMV-IgG negative versus 76.8 among CMV-IgG posi-
tive; P <0.001; Figure 4A). In contrast, there was no asso-
ciation of this immune response with EBV IgG (median
55.4 for negative versus 60.4 for positive; P = 0.32)
(Figure 4A). Of relevance was the lack of association
between CMV-IgG status and the ΔDAS28 (mean dif-
ference −1.2 versus −1.5, P = 0.44).
Higher production of IFN-γ, IL-4, IL-5, IL-12, and IL-13
from PBMC in response to stimulation with CMV/EBV
lysates was observed among CMV-IgG-positive patients
as compared to CMV-IgG-negative patients (Figure 4B).
Table 5 Association of the changes in the immune
response profiles with the changes in clinical disease
activity and disability from baseline to 21 to 24 weeks of
follow up in 43 patients with RA
ΔDAS28 ΔHAQ-DI
Profile Model r P r P
CMV/EBV-1 Unadjusted −0.40b 0.01b −0.36b 0.02b
Adjusteda −0.39b 0.032b −0.39b 0.031b
CMV/EBV-2 Unadjusted −0.03 0.87 −0.15 0.33
Adjusteda 0.07 0.72 −0.10 0.60
PHA-1 Unadjusted 0.12 0.44 0.24 0.13
Adjusteda 0.25 0.17 0.32 0.076
PHA-2 Unadjusted −0.12 0.45 0.00 0.99
Adjusteda −0.05 0.79 0.01 0.94
Media-1 Unadjusted −0.24 0.13 0.00 0.99
Adjusteda −0.37b 0.040b −0.02 0.93
Media-2 Unadjusted −0.25 0.10 −0.10 0.54
Adjusteda −0.38b 0.038b −0.10 0.58
Shown are the Spearman correlation coefficients and associated P-values for the
PCA stimulus-cytokine scores for the first and second principal components and
both the change in the DAS28 and the change in HAQ from baseline to 21 to
24 weeks among 43 patients with early RA. aAdjusted for age, sex, body mass
index, smoking status, rheumatoid factor status, anti-citrullinated protein
antibodies status, CMV immunoglobulin G status, methotrexate use, and
prednisone use; bvalues are statistically significant. ACR, American College of
Rheumatology; DAS28, Disease Activity Score in 28 joints; CMV/EBV,
cytomegalovirus/Epstein-Barr virus; PHA, phytohemagglutinin; HAQ-DI, Health
Assessment Questionnaire disability index.
Figure 2 Associations between the changes in the
cytomegalovirus/Epstein-Barr virus (CMV/EBV) and media-alone
immune response signatures from baseline to 21 to 24 weeks
and clinical response to initial disease-modifying antirheumatic
drug (DMARD) therapy among 43 patients with early rheuma-
toid arthritis. Shown are box plots representing the distributions of
the changes from baseline to 21 to 24 weeks in (A) the CMV/EBV
PCA-1 scores and (B) the media-alone PCA-2 scores, comparing
responders and non-responders. Clinical response was defined as a
decrease in the DAS28 ≥1.2 from baseline to 21 to 24 weeks. The
horizontal dotted lines represent the medians. PCA, principal
components analysis; DAS28, Disease Activity Score using 28 joints.
Figure 3 Clinical improvement in the DAS28 related to
methotrexate treatment compared to other disease-modifying
antirheumatic drugs is uniquely associated with up-regulation
of the cytomegalovirus/Epstein-Barr virus (CMV/EBV) immune-
response signature. Shown are box plots comparing the changes
in the CMV/EBV PCA-1 score from baseline to 21 to 24 weeks of
follow up among 43 patients with early rheumatoid arthritis among
no MTX/non-responders (n = 13), no MTX/responders (n = 10), MTX/
non-responders (n = 7), and MTX/responders (n = 13). The horizontal
center lines indicate the medians, the boxes represent the interquartile
ranges, and the whiskers depict the 2.5 and 97.5 percentiles. DAS28,
disease activity score in 28 joints; PCA-1 score, principal components
analysis-1 score; MTX, methotrexate.
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IFN-γ as well as lower PHA-induced production of IL-12
was evident among CMV-IgG-positive patients as com-
pared to CMV-IgG-negative patients. Otherwise, no other
significant differences in the production of individual cyto-
kines were observed for PHA or CPG (Figure 4B), or any
of the other stimuli (data not shown).Discussion
We report the discovery of a T-cell immune-response
signature associated with CMV immunity that is predict-
ive of inadequate response to initial DMARD therapy
among patients with early RA. Specifically, higher pro-
duction of both type 1 (for example, IFN-γ) and type 2
(for example, IL-4) T-cell cytokines by PBMC, in re-
sponse to stimulation with combined CMV/EBV lysate
ex vivo, is predictive of inadequate DAS28 response to
initial DMARD therapy over 21 to 24 weeks. Because
the CMV/EBV immune-response signature was found to
correlate to CMV IgG serology, the observed association
Figure 4 Exposure to cytomegalovirus (CMV) is associated with the CMV/Epstein-Barr virus (EBV) immune-response signature as well
as generally altered T-cell immunity. (A) Box plots illustrate the distributions of the CMV/EBV PCA-1 score at baseline in 71 patients with RA,
according to CMV and EBV serological status. The horizontal lines represent medians, the boxes represent the 25 to 75 percentiles, and the
whiskers represent the 2.5 to 97.5 percentiles, and dots represent outliers. (B) Scatterplots depict the concentrations of selected cytokines
(based on PCA weightings >0.5) for the immune-response profiles, according to CMV serological status and stimulus (CMV/EBV, PHA, CPG, and media
alone) at baseline in 71 patients with RA. The horizontal bold lines represent the medians; *P <0.05, ***P <0.001. RA, rheumatoid arthritis; DAS28, Disease
Activity Score in 28 joints; PCA, principal components analysis; PHA, phytohemagglutinin; CPG, CpG oligonucleotides; IgG, immunoglobulin-G.
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than EBV immunity. Further, we show that DMARD-
induced amelioration of clinical disease activity correlates
with augmentation of the CMV-related immune-response
signature.With further development, this signature could poten-
tially be useful as a predictive biomarker for individualizing
the management of early RA. Because the patients with
high baseline CMV responsiveness experienced inferior
outcomes of initial DMARD therapy, future studies should
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in these patients could lead to more favorable outcomes.
For example, the hypothesis could be tested that patients
with the high CMV-specific T-cell immune-response
signature would have better clinical response to ther-
apy combining methotrexate and a TNF antagonist.
The significance of this scenario is highlighted by the
knowledge that 50 to 70% of patients fail to respond
to initial methotrexate monotherapy [2,24], yet cur-
rently there are no biomarkers or prediction models
that reliably and accurately identify these individuals
[24-27]. The advent of new techniques for individual-
izing initial therapy could improve outcomes for pa-
tients with RA, by inducing clinical remission earlier
and/or by sparing patients trials of costly and risky medi-
cations to which they are pre-destined to respond un-
favorably [28,29].
The reported immune-response signature clearly re-
quires further refinement and validation. First, we must
verify that CMV is the target of the immune response in
our signature that is predictive of treatment outcome, by
evaluating profiles of cytokine response to CMV and
EBV separately. Removing EBV from the CMV immune
response assay could conceivably reduce both technical
and biological variability in the response profile, resulting
in a more robust and informative assay. Second, we must
determine if this signature is associated with the clinical
response to specific DMARDs or whether it is predictive
of response to disease-modifying therapy in general. In
this regard, a limitation of this study is the heterogeneity
among patients in the selection of DMARD therapy.
Therefore, it will be of interest to determine if the CMV-
related immune-response signature is predictive of suc-
cessful response to treatment with a TNF antagonist or
other biologic agent using a defined protocol. Third, we
recognize that the CMV-related immune-response signa-
ture as undertaken in this study would be challenging to
translate to clinical settings, so further work is necessary
to develop a practical, reliable, and scalable assay based on
our approach. These crucial studies are currently under-
way at our institution.
The findings of this study imply that CMV-related
T-cell immunity may interact with the pathophysi-
ology of RA. A potential unifying hypothesis for our
findings must take into account not only that higher
baseline CMV immune responsiveness is predictive of
inadequate DMARD treatment response, but also that
increasing CMV immune responsiveness from baseline to
follow up is associated with good clinical response to
DMARD therapy. Previous studies have demonstrated
that patients with RA often have impairments of systemic
T-cell function. For example, production of IFN-γ or IL-2
in response to mitogens has generally been found to be
significantly lower in patients with active RA compared toinactive RA or healthy control subjects [30-32]. In con-
trast, Pierer et al. have reported a significantly higher
magnitude of CD4+ IFN-γ-secreting T cells in response to
CMV pp65 or CMV lysate in patients with RA compared
to controls [33]. Effective therapy for RA has been found
to ameliorate the impaired T-cell responsiveness of IFN-γ
production seen in RA patients [30,31,34]. However, our
data suggest that the association between T-cell respon-
siveness and treatment outcome was specific for the
CMV stimulus and not to other T-cell stimuli, includ-
ing CD3/CD28, PHA, CPG, and PMA/ionomycin. Previ-
ous studies have observed the general phenomenon of
RA T-cell hypo-responsiveness using these non-specific
stimuli [30,35,36].
Rather, the findings of this study point to an inter-
action of rheumatoid disease specifically with CMV
immunity. The significant correlation with CMV IgG
suggests that the CMV-induced T-cell immune response
signature is mediated by memory T cells. The nature of
the CMV stimulus and pattern of T-cell cytokines sug-
gest that this signature is mediated by CD4+ cells. Previ-
ous studies have shown that a subset of patients with
RA has expanded pools of CMV-specific CD4+ IFN-γ-
producing T cells in the peripheral blood [33,37,38]. The
distribution of CD4+ memory T cells against CMV is
skewed to higher frequencies of cells in the peripheral
blood than synovial fluid [39]. These cells generally are
thought to have a highly differentiated phenotype, lack-
ing expression of the co-stimulatory molecule CD28,
which has been associated with RA extra-articular mani-
festations and cardiovascular disease [40,41]. Positive
CMV IgG and increased CMV-specific CD4+ CD28null
T cells have been reported to correlate with structural
joint damage [33]. With respect to the relationship be-
tween improvement in clinical disease activity and the
augmentation of the CMV response, our data suggest
that attenuation of inflammation affects the systemic
CMV-specific memory T-cell pool. Speculatively, this
could arise due to changes in the number, function, or
phenotype of CMV-specific memory T cells circulating
in the blood [42,43]. Due to the limitations of this
discovery-oriented study, future research is needed to
clarify the underlying immune mechanisms and implica-
tions of our findings.
We report that among patients who were treated with
methotrexate during follow up and who attained clinic-
ally meaningful DAS28 improvement, the CMV-related
T-cell immune response signature was observed to in-
crease significantly from baseline to follow up. In con-
trast, patients who were treated with non-methotrexate
DMARDs or who did not achieve a meaningful DAS28 re-
sponse generally had a decline in their CMV-associated T-
cell response. The mechanism of this finding is unclear,
and the observational design of this study precludes causal
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plication is that various DMARDs may have different ef-
fects on CMV T-cell responses. Such heterogeneity of
treatment effects on CMV immunity is potentially sig-
nificant in view of the aforementioned association be-
tween CMV IgG and disease progression, suggesting some
DMARDs may not sufficiently antagonize the contribu-
tion of CMV immunity to disease, leading to inadequate
treatment response and disease progression.
Conclusion
We have reported a novel interaction between the clin-
ical response to initial DMARD therapy and an ex vivo
immune response to CMV in patients with early RA.
Together with our published data and findings from re-
cent literature, the results of this study contribute new
insights into the role of a T-cell response associated with
CMV exposure in modulating the outcomes of DMARD
treatment in early RA. The roles of subclinical CMV per-
sistence and CMV-associated T-cell immunity in modulat-
ing the outcomes of RA deserve further investigation.
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